The ASGO Experience With Evidence-Based Clinical Practice Guidelines

Thomas J Smith, Mark R. Somerfield

Research output: Contribution to journalArticle

Abstract

After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalOncology
Volume11
Issue number11 SUPPL. 11A
StatePublished - 1997
Externally publishedYes

Fingerprint

Evidence-Based Practice
Practice Guidelines
Guidelines
Breast Neoplasms
Medical Oncology
Colorectal Neoplasms
Colony-Stimulating Factors
Antiemetics
Diphosphonates
Tumor Biomarkers
Non-Small Cell Lung Carcinoma
Prostatic Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Smith, T. J., & Somerfield, M. R. (1997). The ASGO Experience With Evidence-Based Clinical Practice Guidelines. Oncology, 11(11 SUPPL. 11A), 223-227.

The ASGO Experience With Evidence-Based Clinical Practice Guidelines. / Smith, Thomas J; Somerfield, Mark R.

In: Oncology, Vol. 11, No. 11 SUPPL. 11A, 1997, p. 223-227.

Research output: Contribution to journalArticle

Smith, TJ & Somerfield, MR 1997, 'The ASGO Experience With Evidence-Based Clinical Practice Guidelines', Oncology, vol. 11, no. 11 SUPPL. 11A, pp. 223-227.
Smith, Thomas J ; Somerfield, Mark R. / The ASGO Experience With Evidence-Based Clinical Practice Guidelines. In: Oncology. 1997 ; Vol. 11, No. 11 SUPPL. 11A. pp. 223-227.
@article{6226766cede14c80b268aa4f567fc79b,
title = "The ASGO Experience With Evidence-Based Clinical Practice Guidelines",
abstract = "After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.",
author = "Smith, {Thomas J} and Somerfield, {Mark R.}",
year = "1997",
language = "English (US)",
volume = "11",
pages = "223--227",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 SUPPL. 11A",

}

TY - JOUR

T1 - The ASGO Experience With Evidence-Based Clinical Practice Guidelines

AU - Smith, Thomas J

AU - Somerfield, Mark R.

PY - 1997

Y1 - 1997

N2 - After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.

AB - After strong demand from members, the American Society of Clinical Oncology (ASCO) began, in 1992, to formulate clinical practice guidelines. Guidelines were written for the following: outcomes from cancer treatment, hematopoietic colony-stimulating factors, tumor markers for breast and colorectal cancer, surveillance of breast cancer patients, and management of non-small-cell lung cancer. Further guidelines are being drafted for management of advanced prostate cancer, antiemetics, bisphosphonates in breast cancer and myeloma, chemoprotectants, and surveillance of colorectal cancer patients. This article explores the process by which ASCO guidelines are drafted, as well problems with these guidelines. Suggestions are made for ASCO and other professional groups that anticipate framing a set of guidelines.

UR - http://www.scopus.com/inward/record.url?scp=0031264937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031264937&partnerID=8YFLogxK

M3 - Article

C2 - 9430192

AN - SCOPUS:0031264937

VL - 11

SP - 223

EP - 227

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 SUPPL. 11A

ER -